PS-C36-5: SUPEROXIDE DISMUTASE AS A PROTECTIVE FACTOR FOR EARLY RENAL DAMAGE IN HYPERTENSIVE PATIENTS

Abstract

Background: Hypertension is a primary risk factor for chronic kidney disease (CKD), which is a highly prevalent condition that contributes to a substantial proportion of disease burden globally. However, CKD can be reversed in the early stage of renal damage. As a result, for a better prognosis, early detection and treatment are crucial for a better prognosis. Oxidative stress had been linked to hypertensive renal impairment in previous investigations. Superoxide dismutase (SOD) was a clinically available oxidative stress biomarker that had yet to be linked to early kidney damage in hypertension. The association between SOD and the early renal damage (ERD) of hypertension has not been established. The aim of the study was to investigate the relationship between SOD and ERD, hoping to provide a new direction to prevent and treat hypertension with ERD. Methods: This was a retrospective observational study. Clinical data were collected from patients with essential hypertension (EH) in Shandong Provincial Qianfoshan Hospital from January 2017 to December 2018. ERD was defined as urine microablumin/ creatinine ratio (UACR) greater than 30 mg/g but less than 300 mg/g. Patients were divided into hypertension with ERD group and hypertension without early renal damage (NRD) group. Clinical data from patients were collected and compared between the two groups. Spearman and Pearson correlation analysis were used to analyze the correlation between UACR and SOD. Moreover, univariate and multivariate logistic regression analyses were used to screen for the risk factors for ERD. Results: According to our analysis, SOD was protective factors (P < 0.05). Multivariate logistic regression analysis showed that SOD was an independent protective factor for hypertension with ERD. Both Spearman and Pearson correlation analysis showed negative correlation between SOD and UACR (P < 0.05). Conclusion: SOD was an independent protective factor for early renal damage in hypertensive patients, providing a new direction for the treatment of early renal damage in hypertensive patients.